Virtus ETF Advisers LLC Iveric Bio, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $32,635 - $42,930	-1,748 Reduced 27.8%	4,539 $110,000
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $82,545 - $114,672	-4,788 Reduced 43.23%	6,287 $134,000
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $733 - $1,450	78 Added 0.71%	11,075 $199,000
Q2 2022 Aug 12, 2022	BUY	$9.12 - $18.9 $2,444 - $5,065	268 Added 2.5%	10,997 $106,000
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $7,666 - $10,619	-631 Reduced 5.55%	10,729 $181,000
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $317,135 - $430,644	-22,931 Reduced 66.87%	11,360 $190,000
Q3 2021 Nov 15, 2021	SELL	$7.07 - $17.5 $12,641 - $31,290	-1,788 Reduced 4.96%	34,291 $557,000
Q2 2021 Aug 10, 2021	SELL	$5.69 - $7.17 $40,899 - $51,537	-7,188 Reduced 16.61%	36,079 $228,000
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $3,850 - $5,222	758 Added 1.78%	43,267 $267,000
Q4 2020 Feb 12, 2021	BUY	$5.65 - $7.66 $240,175 - $325,618	42,509 New	42,509 $294,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.